secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0001104659-23-002721
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vericel prelim FY2022 rev ~$164-165M; MACI arthro launch accelerated to 2024; NexoBrid approved
--------------------------------------------------------------------------------

- Full-year 2022 total revenue expected ~$164-165M; MACI rev ~$132M at high end of guidance.
- Q4 MACI revenue growth ~24% YoY; 10th straight quarter of positive adjusted EBITDA and operating cash flow.
- Cash and investments ~$140M, no debt as of Dec 31, 2022.
- NexoBrid FDA approved Dec 28, 2022 for eschar removal in thermal burns; U.S. commercial launch expected Q2 2023.
- MACI arthroscopic delivery human factors study planned for 2023; commercial launch now expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000110465923002721/0001104659-23-002721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000110465923002721/tm232747d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer